Skip to content

OnyxBiotech News

Subscribe About Onyx
Cell & Gene Leaders Live Sunday 15 November 2026 · The Shard (Shangri-La), London · One-day summit for cell & gene therapy leaders Sunday 15 November 2026 · The Shard (Shangri-La), London Get tickets → London Life Sciences Week Guide The unofficial London Life Sciences Week Guide, published by Onyx Newsroom · Every event 15–19 November 2026 Every event 15–19 November 2026 · Published by Onyx Newsroom Plan your week →
News Editor's pick

BOOST Pharma outlines placebo-controlled trial of up to 80 patients for brittle bone cell therapy BT-101 at Meeting on the Mesa

CEO Hans Schambye told Cell & Gene Meeting on the Mesa that BOOST Pharma expects to be able to start a placebo-controlled trial of BT-101, its investigational stem cell therapy for osteogenesis imperfecta, in the middle of next year.

BOOST Pharma CEO Hans T. Schambye speaking at the podium at Cell & Gene Meeting on the Mesa 2026, with the BOOST Pharma logo
Hans T. Schambye, CEO of BOOST Pharma, presenting at Cell & Gene Meeting on the Mesa 2026
Table of Contents

BOOST Pharma used its Innovation Spotlight slot at the Cell & Gene Meeting on the Mesa in Phoenix on Tuesday, October 6, 2026 to set out its plan for a pivotal trial of BT-101, its investigational off-the-shelf stem cell therapy for infants with severe osteogenesis imperfecta (OI), with CEO Hans Schambye saying the company expects to be able to start a placebo-controlled trial in up to 80 patients in the middle of next year.

Schambye said BOOST has been in discussions with the FDA and in Europe, and that “there is alignment” on the need for a placebo-controlled trial of that size. Patients would be treated for a year, he said, with the annualized fracture rate as the primary measure. The company has previously described its pre-IND interaction with the FDA as positive.

“We are basing the number of patients on an expected reduction of 50 percent, where we saw 70 percent reduction in the previous trials, so we think we are being cautious,” he told the room.

He expects the trial to take about 28 months and put its cost at around €20 million.

The headline data come from BOOSTB4, an open-label Phase 1/2 study of 18 patients sponsored by Karolinska Institutet, in which the company has reported a 70% reduction in fractures. Schambye said patients were treated for a year, and the analysis compares fractures before treatment with the first year after treatment stopped. “Every patient had a reduction in the number of fractures,” he said.

Natural history data show children in this age group averaging two to three fractures a year, he said.

OI is a genetic disease in which patients are unable to produce normal collagen. BT-101 is intended to supply cells that reach the bone and, in his words, “start manufacturing the collagen”.

“Think of it like a steel concrete building without the steel,” Schambye said. “You can put in as much concrete as you want, you never get a stable wall. It’s the same for these patients.”

Schambye said the cells are harvested from fetal livers, cryopreserved and transferred to manufacturing partner RoslinCT, then shipped frozen and given as an intravenous infusion. He stressed what is not required, “no preconditioning, no matching is needed, no immune suppression”, attributing this to the cells’ fetal origin.

Schambye said BOOST is in the process of raising a Series A and is “now raising 50 million, which will cover the trial”, along with the manufacturing work needed to support an eventual BLA.

About BOOST Pharma

BOOST Pharma is a clinical-stage biotechnology company based in Copenhagen, Denmark, founded on research from Karolinska Institutet. Its lead program, BT-101, is an allogeneic mesenchymal stem cell therapy for OI, also known as brittle bone disease, which the company says affects an estimated 1 in 15,000 people and has no FDA- or EMA-approved therapies. BT-101 has Orphan Drug Designation in the US and Europe and Rare Pediatric Disease Designation from the FDA.

BOOSTB4 is a Phase 1/2 trial sponsored by Karolinska Institutet, with 18 participants enrolled, in which each patient receives four infusions of first-trimester fetal liver-derived mesenchymal stem cells after birth, or before and after birth. It compares treated children with historical and untreated controls rather than with placebo. In October 2025 BOOST reported two-year follow-up showing an overall fracture reduction of nearly 78% against the pre-treatment period, with more than half of treated patients having no fractures in the second year after the last dose.

BOOST said in January 2026 that it had transferred its manufacturing process to RoslinCT’s facilities in Edinburgh, Scotland. Schambye, previously CEO of Galecto, was appointed CEO in February 2026. The company’s investors include Sound Bioventures, Industrifonden and Karolinska Development (KDventures).


Sources: BOOST Pharma company presentation, Cell & Gene Meeting on the Mesa, October 6, 2026; BOOST Pharma press release; BOOST Pharma company website; ClinicalTrials.gov NCT03706482; BOOST Pharma two-year data release; RoslinCT and BOOST Pharma press release; Sound Bioventures announcement

Coming up: Cell & Gene Leaders Live, Sun 15 Nov at The Shard · London Life Sciences Week Guide, 15–19 Nov 2026 ·

Comments

More News ↗